表紙
市場調査レポート

ファブリー病 - 2024年までの疫学予測

EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 338805
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
ファブリー病 - 2024年までの疫学予測 EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024
出版日: 2015年08月03日 ページ情報: 英文 30 Pages
概要

ファブリー病は、リソソーム酵素であるα-ガラクトシダーゼAの欠損によって生じる、X連鎖性の遺伝子疾患です。世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) でファブリー病と診断された発症件数は、2014年の4,538件から、2024年には8,037件まで、7.71%増加すると予測されています。

当レポートでは、世界の主要7ヶ国におけるファブリー病について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 疫学予測
    • 診断された発症件数
    • 診断された発症件数:年齢別
    • 診断された発症件数:性別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER086-15

Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008). The organ dysfunction is regarded as the first clinical evidence of Fabry disease (Tsuboi et al., 2012). The symptoms of Fabry disease are typically severe in men, whereas women show variable range of symptoms with some being non symptomatic and others showing severe symptoms (Golfomitsos et al., 2012).

GlobalData epidemiologist forecast that the diagnosed prevalent cases of Fabry disease in the 7MM will increase from 4,538 diagnosed prevalent cases in 2014 to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.71% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of Fabry disease, with 3,540 diagnosed prevalent cases, whereas Spain will have the lowest number, with 523 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of Fabry disease in 2024, with 819 diagnosed prevalent cases, and Spain will have the least number, with 523 diagnosed prevalent cases. Japan will have the highest AGR at 8.16%, while Germany will have the lowest AGR at 6.48%.

This report provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex. To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in the 7MM, GlobalData epidemiologists used data available from Fabry Support & Information Group (FSIG) for the US and the EU markets, and the data available for Japan from a population-based study conducted in Japan along with data available from FSIG for Asia-Pacific.

Scope

  • The Fabry Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of Fabry disease segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and comorbidities in these markets.
  • The Fabry Disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global Fabry disease market.
  • Quantify patient populations in the global Fabry disease market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Fabry disease therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities/Manifestations
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases
  • 3.5. Epidemiological Forecast for Fabry disease (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of Fabry disease
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of Fabry disease
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of Fabry disease
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: 7MM, Sources of Fabry Disease Diagnosed Prevalence Data
  • Table 2: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, Selected Years 2014-2024
  • Table 3: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N (Row %), 2014
  • Table 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N, 2014
Back to Top